Casio, the world's leading maker of powerful and affordable musical instruments, announced the U.S. availability of two new entry-level models in its esteemed Celviano digital piano ...

Citi analyst Geoff Meacham maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $295.00. The company’s ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up ...

Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global ...

The market seemed to focus on the sales, and the stock traded up as a result. The shares closed the day at $307.92, up 6.5% from previous close. Is now the time to buy Amgen? Access our full ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

The analysts at Erste Group highlighted Amgen's valuation metrics, pointing to the company's price-to-earnings (P/E) ratio as a key indicator. While InvestingPro analysis suggests the stock is ...